Anti-diabetic drug Repaglinide induces Apoptosis, Cell Cycle Arrest, and Inhibits Cell Migration in Human Breast and Lung Cancer Cells.

This study demonstrates that the anti-diabetic drug repaglinide exerts potent anticancer effects on human breast (MCF-7) and lung (A549) cancer cells by inducing dose-dependent cytotoxicity, triggering apoptosis and G1 cell cycle arrest, and inhibiting cell migration through the downregulation of MMP-2 and MMP-9, thereby supporting its potential as a repurposed therapeutic agent for cancer treatment.

The Gist

Imagine your body is a bustling city. In a healthy city, the construction crews (cells) build new buildings at a steady, controlled pace, and the demolition crews (immune system) remove old or damaged structures efficiently.

Cancer is like a rogue construction crew that has gone haywire. They ignore all stop signs, build chaotic skyscrapers everywhere, refuse to stop working, and even start tearing down the city's walls to spread to new neighborhoods (metastasis).

Repaglinide is a drug originally designed to help manage traffic in a different part of the city: the "Sugar District" (diabetes). It helps regulate insulin levels. But this study discovered that Repaglinide has a secret superpower: it can also act as a super-traffic cop and demolition expert for these rogue cancer crews in the Breast and Lung districts.

Here is how the study explains Repaglinide's new job, broken down into simple steps:

1. The "Stop and Go" Signal (Cytotoxicity)

First, the researchers tested how much Repaglinide it takes to stop the cancer cells. Think of the cancer cells as cars speeding down a highway.

• The Finding: Repaglinide acts like a giant speed bump. The more Repaglinide you add, the slower the cancer cells get, until they stop completely.
• The Result: It took a specific amount of the drug to slow down half of the cancer cells (the "IC50" point). It worked well on both breast and lung cancer cells, showing it's a versatile tool.

2. The "Self-Destruct" Button (Apoptosis)

Cancer cells are stubborn; they refuse to die even when they are damaged. Repaglinide forces them to hit the "Self-Destruct" button.

• The Mechanism: Imagine the cancer cell has a "Life Guard" (a protein called Bcl-2) standing at the door, refusing to let the demolition crew in. Repaglinide kicks the Life Guard out and brings in the "Demolition Crew" (proteins like Bax and Caspases).
• The Damage: The drug also causes damage to the cell's "blueprints" (DNA). When the blueprints are shredded, the cell realizes it can't function and triggers its own suicide program.
• The Outcome: The cancer cells shrivel up, their membranes bubble (like a deflating balloon), and they die off.

3. The "Construction Site Freeze" (Cell Cycle Arrest)

Cancer cells are obsessed with dividing and making copies of themselves. They are always in a rush.

• The Finding: Repaglinide puts a "Do Not Enter" sign on the construction site. It forces the cells to stop at the "G1 checkpoint" (a security gate before they can start building new copies).
• How it works: It lowers the number of "construction managers" (Cyclins and CDKs) needed to start building and boosts the number of "security guards" (p53 and p21) who lock the gates. The cells are stuck in a waiting room, unable to multiply.

4. The "Roadblock" (Stopping Migration and Invasion)

One of the most dangerous things cancer does is pack up and move to other parts of the body (metastasis). To do this, they need to chew through the city walls (the extracellular matrix) using special tools called MMPs (Matrix Metalloproteinases).

• The Finding: Repaglinide takes away the cancer cells' tools. It shuts down the factories that produce MMP-2 and MMP-9.
• The Analogy: Imagine the cancer cells trying to break through a brick wall. Repaglinide doesn't just stop them; it confiscates their sledgehammers and drills. Without these tools, they can't break through the wall to spread to the lungs or other organs.

5. The "Master Switch" (The PI3K/AKT/mTOR Pathway)

All of this happens because Repaglinide flips a master switch inside the cell.

• The Mechanism: There is a main power line in the cell called the PI3K/AKT/mTOR pathway. In cancer, this line is always "ON," telling the cell to grow, survive, and move.
• Repaglinide's Action: It cuts the power to this line. It turns off the "Go" signals and turns on the "Stop" signals (specifically by boosting a protein called PTEN). This shuts down the cancer's engine.

The Big Picture: Why This Matters

This study is a classic example of "Drug Repurposing." Instead of spending 10 years and billions of dollars to invent a brand new drug from scratch, scientists looked at an old, safe, cheap drug already used for diabetes (Repaglinide) and realized, "Hey, this might also stop cancer!"

In summary:
Repaglinide is like a multi-tool for the body. In the context of breast and lung cancer, it:

1. Slows down the cancer's speed.
2. Forces the cancer cells to commit suicide.
3. Freezes their ability to multiply.
4. Confiscates their tools for spreading to other parts of the body.

The researchers conclude that because Repaglinide is already safe for humans (we've been using it for diabetes for years), it could be a very fast and affordable way to treat these cancers if further studies confirm these results in real patients. It's a promising new chapter for an old drug.

Technical Summary

1. Problem Statement

Cancer remains a leading cause of global mortality, characterized by therapeutic resistance, recurrence, and high treatment costs. While drug repurposing offers a cost-effective strategy to identify new indications for existing drugs, the anticancer potential of repaglinide (RPG), a non-sulfonylurea insulin secretagogue used for Type 2 Diabetes Mellitus (T2DM), remains largely unexplored in breast and lung cancers.

• Context: T2DM is epidemiologically linked to an increased risk of breast and lung cancers due to shared mechanisms like hyperinsulinemia and activation of oncogenic pathways (PI3K/Akt, K-Ras).
• Gap: While other antidiabetic classes (e.g., metformin) are well-studied for anticancer effects, meglitinides like RPG have shown promise in glioblastoma and hepatocellular carcinoma but lack systematic evaluation in breast (MCF-7) and lung (A549) cancer models.

2. Methodology

The study utilized in vitro models using human breast cancer (MCF-7) and lung cancer (A549) cell lines to evaluate the cytotoxic, pro-apoptotic, anti-proliferative, and anti-migratory effects of RPG.

• Cell Viability & Morphology: MTT assays were performed to determine IC₅₀ values at 24 and 48 hours. Morphological changes were observed via inverted microscopy.
• Apoptosis Assessment:
  • Dual Staining: Acridine Orange/Ethidium Bromide (AO/EtBr) for morphological visualization.
  • Flow Cytometry: Annexin V-FITC/Propidium Iodide (PI) staining to quantify early and late apoptotic populations.
  • DNA Damage: Neutral Comet assay to detect DNA fragmentation.
  • Molecular Markers: Western blotting and Immunofluorescence (IF) to assess PARP cleavage, Bax/Bcl-2 ratios, and Caspase activation (3, 7, 8, 9).
• Cell Cycle & Clonogenicity:
  • Colony Formation: Long-term survival assay to assess clonogenic potential.
  • Cell Cycle Analysis: Flow cytometry with PI staining to determine phase distribution.
  • Regulatory Proteins: Western blotting for Cyclins (D1, E1), CDKs (2, 6), CDK inhibitors (p21, p16), p53, and the PI3K/AKT/mTOR pathway components (AKT, p-AKT, mTOR, PTEN).
• Migration & Invasion:
  • Scratch Wound Healing: To assess cell motility.
  • Transwell Assays: Migration and Matrigel-coated invasion assays.
  • MMP Analysis: Gelatin zymography and Western blotting for Matrix Metalloproteinases (MMP-2 and MMP-9).
• Mechanistic Validation: Co-treatment with Pifithrin-α (PFR-α), a specific p53 inhibitor, to determine the dependency of RPG's effects on p53.
• Signaling Pathways: Western blotting for MAPK/ERK pathway components (p38, ERK).

3. Key Results

A. Cytotoxicity and Morphological Changes

• RPG reduced cell viability in a dose- and time-dependent manner.
• IC₅₀ (48h): 100.8 ± 3.98 µM for MCF-7 and 104 ± 3 µM for A549.
• Treated cells exhibited classic apoptotic morphology: cell shrinkage, membrane blebbing, loss of adhesion, and irregular shapes.

B. Induction of Apoptosis

• Morphological Evidence: AO/EtBr staining showed a significant increase in early (yellow-green) and late (orange-red) apoptotic cells.
• Quantitative Evidence: Flow cytometry confirmed a dose-dependent increase in the apoptotic population (e.g., MCF-7 apoptosis rose from 0.25% in controls to 16.19% at 80 µM RPG).
• Molecular Mechanism:
  • DNA Damage: Comet assay revealed significant DNA fragmentation and increased Olive Tail Moment.
  • PARP Cleavage: Western blot showed reduced full-length PARP and increased cleaved PARP.
  • Mitochondrial Pathway: Upregulation of Bax and Caspase-9, downregulation of Bcl-2, and activation of Caspase-3 and Caspase-7.
  • Extrinsic Pathway: Activation of Caspase-8 was also observed.

C. Cell Cycle Arrest and Anti-proliferation

• Clonogenicity: RPG significantly suppressed colony formation in a dose-dependent manner.
• Cell Cycle Arrest: RPG induced G1 phase arrest.
  • MCF-7: G1 population increased from 67.66% (control) to 74.79% (80 µM).
  • A549: G1 population increased from 49.00% (control) to 70.08% (80 µM).
• Molecular Drivers:
  • Upregulation: p53, p21, and p16.
  • Downregulation: Cyclin D1, Cyclin E1, CDK2, and CDK6.
  • Pathway Inhibition: RPG suppressed the PI3K/AKT/mTOR pathway (decreased p-AKT, mTOR) and upregulated the tumor suppressor PTEN.

D. Inhibition of Migration and Invasion

• Motility: Scratch wound assays showed RPG significantly reduced wound closure (e.g., MCF-7 closure dropped from 74% to 6% at 80 µM).
• Invasion: Transwell assays confirmed reduced migration and invasion through the extracellular matrix.
• MMP Regulation: RPG treatment led to a dose-dependent decrease in the enzymatic activity and protein expression of MMP-2 and MMP-9.
• Signaling: RPG modulated the MAPK/ERK pathway (downregulating p38 and ERK in MCF-7; primarily p38 in A549), which correlates with MMP suppression.

E. Role of p53

• Treatment with Pifithrin-α (p53 inhibitor) partially reversed RPG-induced apoptosis and cell cycle arrest.
• This indicates that RPG's anticancer effects are partially mediated by p53, though p53-independent pathways also contribute.

4. Key Contributions

1. Novel Repurposing Candidate: Establishes Repaglinide as a potent anticancer agent for breast and lung cancers, expanding its utility beyond diabetes management.
2. Dual Pathway Activation: Demonstrates that RPG triggers both intrinsic (mitochondrial) and extrinsic apoptotic pathways, a mechanism often associated with overcoming drug resistance.
3. Mechanistic Elucidation: Defines a coordinated molecular network where RPG:
   • Induces DNA damage $\rightarrow$ Stabilizes p53 $\rightarrow$ Upregulates p21/p16 $\rightarrow$ G1 Arrest.
   • Inhibits PI3K/AKT/mTOR $\rightarrow$ Restores PTEN $\rightarrow$ Suppresses proliferation.
   • Downregulates MAPK/ERK $\rightarrow$ Reduces MMP-2/9 $\rightarrow$ Inhibits metastasis.
4. Cell-Type Specificity: Highlights that while the overall mechanism is consistent, the modulation of MAPK/ERK components (specifically ERK vs. p38) varies between MCF-7 and A549 cells.

5. Significance

• Therapeutic Potential: The study provides a strong rationale for repurposing Repaglinide, leveraging its established safety profile, favorable pharmacokinetics, and low cost.
• Metabolic-Cancer Link: It reinforces the biological connection between metabolic dysregulation (diabetes) and tumorigenesis, suggesting that targeting metabolic regulators can effectively disrupt oncogenic signaling.
• Metastasis Control: By inhibiting MMP-2 and MMP-9 via the PI3K/AKT and MAPK pathways, RPG offers a potential strategy to prevent cancer metastasis, a critical unmet need in breast and lung cancer therapy.
• Future Directions: The findings justify further in vivo studies and clinical trials to evaluate RPG as an adjunctive therapy for metabolically associated malignancies.